10x Genomics, Inc. - TXG STOCK NEWS

10x Genomics (Nasdaq: TXG) will release its Q1 2021 financial results on May 5, 2021, after market close. A live webcast is scheduled for 1:30 PM PT to discuss these results along with business developments and future outlook. The webcast will be accessible through the company's website and will be archived for at least 45 days. 10x Genomics focuses on providing innovative life science technology solutions that enhance biological research and has a robust patent portfolio.

10x Genomics, Inc. (TXG) announced the launch of its Chromium Single Cell Gene Expression Low Throughput (LT) Kit, aimed at making single cell analysis more accessible to researchers. This innovative kit significantly reduces the startup costs for experiments. The LT Kit is designed for experiments ranging from a few hundred cells to high-throughput studies.

Additionally, the CellPlex solution allows multiplexing of up to 96 samples on a single chip, enhancing experimental capability. Both products facilitate cost-effective research and are part of 10x Genomics' commitment to democratizing scientific discovery.

10x Genomics (TXG) has announced significant expansion plans in Pleasanton, California, involving a $29.4 million acquisition of the former Pleasanton Plaza retail complex. The new site at 1701 Springdale Avenue will feature 381,000 square feet of lab space and a parking garage, with completion expected by 2023. This move reinforces the company’s commitment to its headquarters, where it has grown to over 900 employees. Pleasanton will rename Fabian Court to 'Genomics Place' in recognition of 10x's investment.

10x Genomics (Nasdaq: TXG) announced its participation in the 41st Annual Cowen Health Care Conference on March 3 at 2 p.m. Eastern Time. The presentation will be accessible via a live and archived webcast on the company's website. 10x Genomics is focused on advanced life science technologies, with products adopted by top research institutions and pharmaceutical companies globally. The company boasts a robust patent portfolio with over 1,000 patents and has been cited in over 2,200 research papers in various fields.

10x Genomics (Nasdaq: TXG) has announced the acquisition of Tetramer Shop and unveiled new products at its Xperience 2021 event. This marks the fifth acquisition for the firm, aimed at bolstering its immunology efforts. The newly introduced products focus on single-cell analysis, with significant capabilities like the Low Throughput Single Cell Gene Expression solution, expected to lower startup costs by up to 60%. Other upcoming innovations include Chromium X, Visium advancements, and a new cloud platform for data analysis, enhancing accessibility for researchers.

10x Genomics reported Q4 2020 revenue of $112.2 million, a 49% increase from the previous year, and a full-year revenue of $298.8 million, up 22% year-over-year. The company had a gross margin of 83% in Q4, up from 78% in Q4 2019, driven by a shift in product sales. However, operating expenses surged to $502.9 million, resulting in an operating loss of $409.6 million. For 2021, 10x Genomics projects revenue between $480 million and $500 million, reflecting a growth outlook of 61% to 67%.

10x Genomics (TXG) has announced that it will release its financial results for Q4 and full year ended December 31, 2020, after the market close on February 17, 2021. A conference call to discuss the results and company outlook will begin at 1:30 PM PT. The event will be accessible via webcast on the company's website and archived for replay for 45 days. 10x Genomics focuses on life science technology, providing solutions that enhance biological understanding, serving major global research institutions and pharmaceutical companies.

10x Genomics (Nasdaq: TXG) will participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference, scheduled for January 11, 2021, at 7:00 a.m. PT / 10:00 a.m. ET. The company's management will present key information, and interested parties can access a live and archived webcast on their Investors page.

10x Genomics develops integrated solutions for biological research, with products widely adopted by leading research institutions and pharmaceutical companies.

10x Genomics, Inc. (TXG) reported Q3 2020 revenue of $71.8 million, a 17% increase year-over-year and a 67% increase from Q2 2020. The company made significant acquisitions of ReadCoor and CartaNA, enhancing its capabilities in In Situ analysis. Despite revenue growth, operating expenses surged 124% to $122.7 million, leading to an operating loss of $65.3 million and a net loss of $65.8 million. The company has withdrawn its full-year revenue guidance due to ongoing COVID-19 uncertainties.